Ascletis Pharma Inc. has announced that a petition for Post Grant Review has been filed with the United States Patent and Trademark Office by Conjupro Biotherapeutics, Inc., a subsidiary of CSPC Pharmaceutical Group Limited. The petition challenges the validity of specific claims in one of Ascletis Pharma's granted U.S. patents. The patent in question covers the molecular structure of Compound 1, which is identical to Compound 10 in CSPC's pending patent application. Ascletis had filed its patent application approximately three months before CSPC's application. The petition is currently under review by the USPTO, and its potential impact on Ascletis cannot be determined at this stage. The company will monitor developments closely and inform shareholders and investors of any significant updates.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.